Eremophilone is one of the signature oxygenated sesquiterpene ketones of Buddha wood and one of the clearest chemistry-defining constituents in the AromaForge archive. Compared with many minor terpenes, its evidence base is stronger for identity, occurrence, and constituent-level preclinical cytotoxicity research in Eremophila mitchellii fractions. That evidence remains experimental rather than clinical, so the archive should present eremophilone as a rare wood-oil marker with notable preclinical bioactivity signals, not as an established human therapeutic ingredient.
Chemical identity and composition
PubChem REST data identifies eremophilone as CID 21591457 with formula C15H22O and IUPAC name (3S,4aR,5S)-4a,5-dimethyl-3-prop-1-en-2-yl-2,3,4,5,6,7-hexahydronaphthalen-1-one. The Good Scents Company supports CAS 562-23-2 and lists the same core stereochemical name. In the local archive, public Buddha wood GC/MS records place eremophilone as a dominant constituent, and a broader Eremophila review reports wood-oil profiles where eremophilone exceeds 50%.
Aroma and practical use
- Use the recorded woody, dry, earthy, camphoraceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
dominant occurrence in buddha wood
A reviewed 2025 Buddha wood GC/MS report lists eremophilone at 31.74%, confirming it as one of the dominant oxygenated sesquiterpenes in that batch.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
constituent level cytotoxicity research
The accessible abstract reports that eremophilone and related purified eremophilanes from Eremophila mitchellii exhibited cytotoxicity against P388D1 mouse lymphoblast cells in vitro.
Measured: in-vitro cytotoxicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
species level composition anchor
A directly readable review table for Eremophila mitchellii wood oil reports eremophilone at 50.6% in one wood-oil profile, reinforcing its role as a primary Buddha wood marker constituent.
Measured: reported abundance in Eremophila mitchellii wood oil
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The Good Scents Company lists eremophilone as a natural substance and extractive and notes 'not for fragrance use' and 'not for flavor use,' but does not provide a public constituent-specific dermal limit or toxicology narrative.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No human clinical safety trials, modern sensitization review, or phototoxicity study specific to isolated eremophilone were located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Buddha wood whole-oil safety summaries should not be treated as direct proof of isolated eremophilone safety.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
cell growth inhibition signal
The accessible Eremophila mitchellii abstract supports a cell-growth-inhibition signal for purified eremophilanes including eremophilone in a mouse lymphoblast assay, but no deeper pathway-level clinical mechanism was verified in this pass.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies specific to isolated eremophilone were located in the reviewed public sources.
- The verified bioactivity evidence remains preclinical and centered on cytotoxicity models rather than consumer-relevant human outcomes.
- Constituent-specific dermal-limit, sensitization, and phototoxicity data were not located in the reviewed public sources.
- 2026-07-13 verification pass: web search for IFRA/RIFM dermal limit and sensitization data found no authoritative constituent-specific results; prior dermal_limit_pct (2) was an unsourced placeholder and has been corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.